West syndrome is a rare form of neurological disorder, an age-related specific Epileptic Encephalopathy. West Syndrome can lead to a number of symptoms such as seizures known as epileptic (infantile) spasms, gross EEG abnormalities of hypsarrhythmia and intellectual disability.
The total West syndrome diagnosed prevalent population in the 7MM was 8,601 in 2020, with a higher predisposition in females. As per DelveInsight, the West syndrome market is expected to increase at a CAGR of 5.8% in the 7MM during the study period (2018–30).
The treatment of West Syndrome is challenging with available therapy options in the market. To address the prevailing unmet needs, pharma companies such as GW Pharmaceuticals plc, BioPharm Solutions, Insys Therapeutics, and others are developing therapies to bridge the treatment gap.
Read More: West Syndrome Market Growth Analysis